This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Davis, R L Articles by Smith, A L Search for Related Content PubMed PubMed Citation Articles by Davis, R L Articles by Smith, A L

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1985 July; 28(1): 74-77

Pharmacokinetics of three oral formulations of ciprofloxacin.

R L Davis, J R Koup, J Williams-Warren, A Weber and A L Smith

ABSTRACT

We compared the absorption of three formulations of ciprofloxacin after oral administration in 18 normal adult male volunteers. Each subject received 500 mg of ciprofloxacin as two 250-mg tablets, one 500-mg tablet, or a solution in a randomized crossover sequence. Pharmacokinetic parameters were determined by model independent methods. Because a solution is considered to be the ideal oral dosage form, the results determined for the tablets were compared to those for the solution. Mean values for the maximum concentration of drug in serum, the time to maximum concentration of drug in serum, and the elimination half-life were 3.23 micrograms/ml, 1.00 h, and 5.04 h, respectively, for the solution. The mean renal clearance of ciprofloxacin was 372 ml/min and accounted for at least 50% of the total clearance. We recovered 44.4, 48.6, and 55.8% of the administered ciprofloxacin from the urine as unchanged drug within 24 h after dosing with the 250-mg tablets, 500-mg tablets, or solution, respectively. The 500-mg tablets were found to be bioequivalent to the solution with regard to all pharmacokinetic parameters. The 250-mg tablet was not bioequivalent to either of the other formulations; the relative bioavailability values were 78.7 and 74.1%, respectively, for the 500-mg tablet and the solution. The clinical significance of this difference in bioavailability is yet to be determined.

---

Antimicrob Agents Chemother. 1985 July; 28(1): 74-77

This article has been cited by other articles:

• How, P. P., Fischer, J. H., Arruda, J. A., Lau, A. H. (2007). Effects of Lanthanum Carbonate on the Absorption and Oral Bioavailability of Ciprofloxacin. CJASN 2: 1235-1240 [Abstract] [Full Text]  
• Bennish, M. L., Salam, M. A., Khan, W. A., Khan, A. M. (1992). Treatment of Shigellosis: III. Comparison of One- or Two-Dose Ciprofloxacin with Standard 5-Day Therapy: A Randomized, Blinded Trial. ANN INTERN MED 117: 727-734 [Abstract]